{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:58:38Z","timestamp":1777485518124,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both domestic and foreign guidelines recommend that chronic hepatitis B virus (HBV) infection pregnant women in the immune tolerance phase (ITP) discontinue antiviral therapy after delivery, this study aimed to investigate the risk of postpartum drug withdrawal and the pros and cons of continuing treatment of tenofovir dipivoxil fumarate (TDF) in ITP pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study group consisted of 116 naive pregnant women in ITP, the control group included 81 naive chronic hepatitis B (CHB) pregnant women with HBeAg-positive and high viral load. The study aimed to compare the risk of discontinue rebound within 48 weeks postpartum, the antiviral efficacy and bone and renal safety of continuing TDF treatment until 144 weeks postpartum between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no significant difference in the reduction of HBV DNA levels between the ITP group and the CHB group prior to labor (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05), with a 100% success rate in mother-to-child transmission prevention for both cohorts. Postpartum, 38.8% (45\/116) and 18.5% (15\/81) of parturients in the ITP group and CHB group, respectively, discontinued TDF at various time intervals. Comparative analysis of the risk of viral rebound within 48 weeks postpartum revealed no significant difference between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). The ITP group had higher rates of suboptimal response and low viremia occurrence compared to the CHB group (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05) at 48 weeks postpartum, but following salvage therapy up to 144 weeks postpartum, the cumulative rate of complete virological response(CVR) in the ITP group was non-inferior to that in the CHB group (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). There were no significant differences in the average eGFR and serum phosphorus levels between the two groups from baseline to 144 weeks after TDF treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Postpartum discontinuation of TDF poses significant risks for immunotolerant pregnant women, whereas continuing TDF treatment for 144 weeks postpartum demonstrates favorable antiviral efficacy, bone and renal safety profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1597664","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:13Z","timestamp":1762492873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune tolerance"],"prefix":"10.3389","volume":"12","author":[{"given":"Huan","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengkai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tumei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.2174\/1381612826666201210113841","article-title":"Pregnancy and viral hepatitis: current concepts.","volume":"27","author":"Tagkou","year":"2021","journal-title":"Curr Pharm Des."},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annepidem.2020.05.011","article-title":"Prevalence of hepatitis B virus infection and its associated factors among 15,461 pregnant women in Yunnan province, China.","volume":"49","author":"Liu","year":"2020","journal-title":"Ann Epidemiol."},{"key":"B3","year":"2016","journal-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101050","DOI":"10.1016\/j.jhepr.2024.101050","article-title":"Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection.","volume":"6","author":"Chen","year":"2024","journal-title":"JHEP Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12072-022-10412-w","article-title":"Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection.","volume":"17","author":"Li","year":"2023","journal-title":"Hepatol Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma.","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses."},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3760\/cma.j.cn112141-20200213-00101","article-title":"[Clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus (2020)].","volume":"55","year":"2020","journal-title":"Zhonghua Fu Chan Ke Za Zhi."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13596535221083179","DOI":"10.1177\/13596535221083179","article-title":"Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.","volume":"27","author":"Razavi","year":"2022","journal-title":"Antivir Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.pedneo.2019.01.002","article-title":"Maternal HBeAg positivity and viremia associated with umbilical cord blood hepatitis B viremia.","volume":"60","author":"Lee","year":"2019","journal-title":"Pediatr Neonatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jvh.13511","article-title":"Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone.","volume":"28","author":"Yao","year":"2021","journal-title":"J Viral Hepat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4103\/sjg.sjg_336_22","article-title":"Shedding light on the gray zone: hepatic fibrosis in chronic hepatitis B patients with fluctuating HBV DNA levels.","volume":"28","author":"Brown","year":"2022","journal-title":"Saudi J Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0212737","DOI":"10.1371\/journal.pone.0212737","article-title":"Lowering the upper limit of serum alanine aminotransferase levels may reveal significant liver disease in the elderly.","volume":"14","author":"Schmilovitz-Weiss","year":"2019","journal-title":"PLoS One."},{"key":"B14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis b patients considered immune tolerant.","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41598-019-39043-2","article-title":"Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals.","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.","volume":"67","author":"Kim","year":"2018","journal-title":"Gut."},{"key":"B17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MEG.0000000000002476","article-title":"Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment.","volume":"35","author":"Feng","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.14218\/JCTH.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic Hepatitis B (Version 2022).","volume":"3","author":"Hong","year":"2023","journal-title":"Infect Dis Immunity."},{"key":"B19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12072-021-10285-5","article-title":"Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy.","volume":"16","author":"Kumar","year":"2022","journal-title":"Hepatol Int."},{"key":"B20","year":"2020","journal-title":"Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1112234","DOI":"10.3389\/fimmu.2022.1112234","article-title":"Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection.","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3760\/cma.j.cn501113-20220209-00060","article-title":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B.","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.3969\/j.issn.1001-5256.2021.10.007","article-title":"Expert consensus on diagnosis and treatment of chronic hepatitis B virus with persistently normal alanine aminotransferase.","volume":"37","year":"2021","journal-title":"J Clin Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1093\/cid\/ciac385","article-title":"Simplifying treatment criteria in chronic Hepatitis B: reducing barriers to elimination.","volume":"76","author":"Wong","year":"2023","journal-title":"Clin Infect Dis."},{"key":"B25","year":"2024","journal-title":"Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection."},{"key":"B26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/apt.15901","article-title":"Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.","volume":"52","author":"Lampertico","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"ofad404","DOI":"10.1093\/ofid\/ofad404","article-title":"Renal safety of long-term tenofovir disoproxil fumarate treatment in patients with chronic Hepatitis B.","volume":"10","author":"Woldemedihn","year":"2023","journal-title":"Open Forum Infect Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1597664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:15Z","timestamp":1762492875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1597664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1597664"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1597664","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1597664"}}